Epidemiologic studies and novel clinical research approaches that impact TB vaccine development  by Evans, Thomas G. et al.
lable at ScienceDirect
Tuberculosis 99 (2016) S21eS25Contents lists avaiTuberculosis
journal homepage: http : / / int l .e lsevierhealth.com/journals / tubeCONFERENCE REPORTEpidemiologic studies and novel clinical research approaches that
impact TB vaccine development
Thomas G. Evans a, *, Gavin J. Churchyard b, c, Adam Penn-Nicholson d, Chen Chen e,
Xu Gao f, g, Dereck R. Tait h, Mark Hatherill d
a Aeras, Rockville, MD, USA
b Aurum Research Institute, Johannesburg, South Africa
c School of Public Health, University of Witwatersrand, South Africa
d South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology,
University of Cape Town, Cape Town, South Africa
e Aeras, Beijing, China
f Fudan University, Shanghai, China
g Heidelberg University, Heidelberg, Germany
h Aeras, Cape Town, South AfricaKeywords:
Tuberculosis
Clinical trial
Epidemiology* Corresponding author. Aeras, 1405 Research Blvd,
E-mail address: tevans@aeras.org (T.G. Evans).
http://dx.doi.org/10.1016/j.tube.2016.05.008
1472-9792/© 2016 The Authors. Published by Elsevies u m m a r y
The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 e 24 April 2015, brought
together a wide and diverse community involved in tuberculosis vaccine research and development to
discuss the current status of, and future directions for this critical effort. This paper summarizes the
sessions on Developing TB Vaccines for Prevention of Disease, Prevention of Infection, and Immuno-
therapy Indications; Concepts and Approaches in Clinical Research & Development; and Epidemiological
Research. Summaries of all sessions from the 4th Global Forum are compiled in a special supplement of
Tuberculosis. [August 2016, Vol 99, Supp S1, S1eS30].
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Tuberculosis (TB) vaccine efﬁcacy trials are large, expensive and
complex. In order to show the efﬁcacy of a vaccine to prevent TB
disease in a population with 1% TB incidence, at least 100 subjects
need to be enrolled to accumulate a single TB disease endpoint.
The cost of such trials results in the need to focus on speciﬁc
populations that will lead to the greatest knowledge with the
fewest subjects enrolled, to have an understanding of the epide-
miology and endpoints that allow for appropriate powering as-
sumptions, and to use novel designs to decrease clinical sample
size. The 4th Global Forum featured a series of sessions that
focused on these issues, and brought to light some of the newest
developments and ongoing studies in this arena.Rockville, MD 20850, USA.
r Ltd. This is an open access article2. TB vaccines for what purpose: prevention of infection,
prevention of disease, prevention of recurrence
2.1. Overview of potential target indications
Dr. Mark Hatherill (South African Tuberculosis Vaccine Initiative
e SATVI, South Africa) in a session entitled “Developing TB vac-
cines: for what purpose?” gave an overview of the potential in-
dications for TB vaccines, excluding therapeutic studies that would
shorten active TB drug therapy. These potential indications for TB
vaccines included Prevention of Infection (POI), Prevention of Dis-
ease (POD), and Prevention of Recurrence (POR).
Of the vaccines currently in clinical testing, most candidate
vaccines are aimed at POD [1]. An effective POD vaccine is desir-
able as such a candidate could be used in Mycobacterium tuber-
culosis (Mtb) uninfected and infected individuals and have a more
rapid impact on the TB epidemic than a POI vaccine, by inter-
rupting transmission of TB from infectious adults. Issues with PODunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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slow accrual of TB disease endpoints. Meta-analyses have
demonstrated that protection against TB disease following BCG
vaccination is consistently better in infants and tuberculin skin test
(TST) negative children than in adults and TST positive children [2].
A concern exists that in adult POD studies, pre-existing anti-
mycobacterial immunity, as evidenced in interferon gamma
release assay (IGRA)-positive individuals, may block the effects of
TB vaccines. This may be particularly problematic for live vaccines
such as BCG and new recombinant BCG constructs, as well as live
attenuated Mtb vaccine candidates Such pre-existing immunity
might inhibit the limited replicative ability of live vaccines, which
is considered to be crucial in inducing optimal protection. The
possibility that pre-existing Mtb immunity might also mask the
response to boosting with a subunit or viral-vectored vaccine
seems less likely, given that Mtb infected individuals have shown
greater immunological responses to these experimental vaccines
than did uninfected individuals [3,4]. POD as an indication is also
likely to be the preferred indication from a regulatory point of
view, since the microbiologically conﬁrmed TB disease endpoint is
an accepted gold standard.
For POD studies, the question of whether to enroll Mtb unin-
fected or naïve subjects remains a vexing issue. A study using IGRA
as an indicator of Mtb infection that was conducted in over 6000
BCG vaccinated adolescents in South Africa [5] demonstrated that
the rate of TB disease in Mtb infected individuals is 3-fold higher
than in Mtb uninfected individuals, and 8-fold higher in Mtb
negative individuals who become infected compared to those who
remain Mtb uninfected. Overall, a meta-analysis of similar studies
revealed that IGRA positive subjects have 2.1 fold increased risk of
disease overall, compared to IGRA negative subjects followed for
equal lengths of time [6]. For this reason, the present ongoing phase
2b M72/AS01E POD study conducted by Aeras and GSK in 3500
subjects at ten sites in three African countries is only enrolling IGRA
positive subjects [7].
The premise for the POI indication is that a TB vaccine that
effectively prevents TB infection would prevent subsequent TB
disease in these individuals [8]. The POI indication is an attractive
hypothesis to test, since the high annual rate of infection with Mtb
compared to active TB disease requires 8e10-fold fewer subjects in
a POI trial compared to an equivalently powered POD study. A
number of observational and cohort studies with BCG lend
credence to the possibility that BCG vaccination in early life may
prevent infection (as measured using IGRA assays) over longer
periods of time, with a 27% overall efﬁcacy observed in a recently
published meta-analysis of such studies [9]. The major beneﬁt of
an effective POI vaccine would be in those who have not previously
been Mtb infected, such as neonates, children and adolescents.
Whether a POI approach would also be beneﬁcial in areas with
high force of infection and therefore high reinfection rates has not
yet been demonstrated, but modeling studies suggest that high
frequency of Mtb exposure is unlikely to affect the ability to
demonstrate efﬁcacy of an effective POI vaccine [8]. There has been
ongoing debate over whether the IGRA endpoint could be used for
licensure, as it is possible that Mtb infection is only prevented in
those who would not otherwise progress to disease, and therefore
there would be no effect on actual TB disease and TB transmission
rates. Doubts about the suitability of using IGRA as endpoint, due
to variability around the test threshold and high rates of reversion
in low TB burden settings, have been mostly allayed by the good
concordance with TST and strong association between IGRA con-
version and risk of TB disease in high TB burden settings [10].
A major issue in POI trials nevertheless remains the fact that
IGRA conversions (a marker of recent Mtb infection) are not always
sustained and reversions to negative frequently occur. Data fromanimal models and human studies from the pre-chemotherapeutic
era suggest that TST reversion is associated with reduced risk of
incident TB disease [11,12]. There are conﬂicting recent data as to
whether such ‘reverting’ individuals are more or less likely to
develop TB disease than individuals with sustained conversions
[13]. To test the POI approach, SATVI and the Desmond Tutu TB
Center at the University of Cape Town have completed enrolment of
990 school age adolescents in a phase 2 POI trial testing either the
H4:IC31 vaccine or BCG revaccination to prevent Mtb infection [14].
Primary results will be available by the end of 2016.
POR studies are attractive for a number of reasons: the TB
disease endpoint accrual will be higher than that in POD studies,
requiring approximately 4e8 fold fewer participants and shorter
duration (2e8% TB patients who complete treatment present with
recurrent disease within one year, whether by relapse or re-
infection [15]). This in turn allows these studies to be used, in
the same way POI studies could be used, as a method of selecting
vaccines for large and expensive phase 3 POD studies. Additionally,
immunotherapeutic use of TB vaccines, such as following
completion of TB treatment, could be attractive as a public health
measure to reduce the incidence of recurrent TB disease, which
places an enormous burden on National TB Programs. A POR vac-
cine would be a particularly attractive prospect for treating
multidrug-resistant (MDR) TB and extensively drug-resistant
(XDR) TB, for which treatment regimens are much longer, more
arduous, and expensive. Candidate vaccines for use in POR in-
dications already have demonstrated some feasibility in animal
models [16,17] and in humans (e.g., as a treatment shortening
regimen with Mycobacterium vaccae in China [18]).
In a further discussion on the use of POR, Nunn et al. reported
that greater than 90% of recurrent TB cases occurred within 12
months of end of treatment [19], and a rate of 5.4% in the ﬁrst
twelve months after treatment was reported in Malawi [20].
Recurrence of TB disease after successful treatment could be due to
either relapse or reinfection, with reinfection rates remaining static
and relapse rates declining with time. Post-treatment relapse could
be assumed as a model for reactivation from latent infection. If a
vaccine were to protect against relapse, an efﬁcacy trial in pre-
vention of active TB in latently Mtb infected (LTBI) populations
would be warranted. Additionally, if a POR vaccine protected
against reinfection, it wouldmore likely be able to prevent infection
in previously uninfected populations.
2.2. Potential population level impact of new TB vaccines
Dr. Richard White (London School of Hygiene and Tropical
Medicine - LSHTM, UK) spoke on the potential public health impact
of new TB vaccines with POI or POD effects. He noted that new POI
vaccines would be expected to have a large impact on Mtb infec-
tion, but a slower impact on TB disease andmortality burden than a
post-infection POD vaccine. In contrast a post-infection POD vac-
cine would be expected to have a faster impact on TB disease, have
biggest impact before 2035/2050 if targeted at adolescents, adults
[21], or the elderly, and will be needed to reach World Health Or-
ganization (WHO) 2035/2050 goals. He also noted that to reduce TB
in 0e4 year olds, targeting adults with post-infection POD may
have quicker impact than vaccinating <1 year olds directly.
Practically, a clearly signiﬁcant advantage of the POI strategy
may be the ability to utilize already existing infant/childhood
vaccination programs for delivery of new TB vaccines. However, a
signiﬁcant issue for implementation of a POD vaccine directed at
adults is the lack of an existing vaccination platform such as exists
for infants and children. This may be overcome by administration of
the vaccine to adolescents at schools along with human papilloma
virus (HPV) vaccines, through mass immunization campaigns, by
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campaigns, or as part of occupational health systems or well-
women clinics.
3. Concepts and approaches in clinical research
Dr. Tom Evans (Aeras, USA) discussed novel clinical and
immunological concepts to assist in reducing risk, cost and sample
sizes required for testing candidate vaccines, and methods to
accelerate development of the most promising vaccine candidates
towards efﬁcacy trials. Possible new trials testing POR and POI
indications of candidate vaccines were further discussed, but
without known correlates of protection, intensive immunological
studies need to be incorporated into the preclinical vaccine eval-
uation strategies. Such studies could incorporate systems biology
analysis, immune cell phenotypes, and in vitro and in vivo myco-
bacterial growth inhibition assays. They could also be followed by
larger studies that would use these tools to evaluate correlates of
treatment success or disease recurrence. Evans also emphasized
the importance of aerosol delivery of TB vaccines to induce local
mucosal immunity in protection against pulmonary TB. He
addressed the pressing need for a human TB challenge model and
presented the key feature of optimal human TB challenges strain
candidates. Given the lack of comprehensive doseeresponse
investigation in the vaccine ﬁeld, he suggested that TB vaccine
developers follow the drug ﬁeld by developing and using mathe-
matical modeling to drive early trial designs for dose regimen
optimization.
Dr. Grace Kiringa (Kenya Medical Research Institute -KEMRI,
Kenya) presented progress in implementation, recruitment and
follow up of participants in a phase 2b study to test efﬁcacy of
GSK's M72/AS01E vaccine in Kenya. Other sites include eight cen-
ters in South Africa and two in Zambia. KEMRI has been successful
in its participation as a site for the AERAS-402/CrucellAd35 vaccine
testing in infants, contributing >50% of enrolled babies [22]. Close
collaboration with local administration, village leadership, reli-
gious leaders and community members helps attain recruitment
and retention in follow-up. Concerns about study participation are
centered on the local taboo issues of blood collection and
the requirement for contraception prior to and during study
participation.
In an approach to investigate immunological synergy between
two vaccine candidates, Dr. Iman Satti (University of Oxford, UK)
discussed results of a phase 1 trial conducted in TB-negative, BCG-
vaccinated adults living in the UK who received one or two intra-
muscular doses of a hAd35-vectored vaccine containing Ag85A,
Ag85B, and TB10.4 followed by intradermal administration of MVA
Ag85A, compared to three intramuscular doses of the adenoviral
vector alone. CD4þ and CD8þ T-cell IFN-g responses were signiﬁ-
cantly increased following the heterologous MVA85A boost of the
hAd35 vaccine, but not after a second or third homologous hAd35
vaccination. Similar trial designs utilizing combination approaches
may help to inform future optimal vaccination regimens, and lead
to novel advances in TB vaccinology.
Dr. Xuefeng Yu (CanSino Biotech Inc., China) presented the
progress of his company on utilizing mucosal delivery of Ad5Ag85A
to boost parental BCG immunization. In animal models, including
the mouse, guinea pig, goat and cow, intranasal vaccination with
Ad5Ag85A generated memory T-cells on the surface of respiratory
mucosa and provided superior lung protection to pulmonary TB
compared to either intramuscular (IM) vaccination or BCG [23].
Ad5Ag85A given intramuscularly was safe in a phase 1 study con-
ducted in Canada and elicited CD4þ and CD8þ T-cell responses [24].
Unexpectedly, in that study pre-existing anti-Ad5 immunity did not
signiﬁcantly affect the immunogenicity of the Ad5Ag85A vaccine.To support the application of Ad5-vectored vaccine as booster to
BCG vaccination, Dr. Yu presented preliminary data of Ad5Ag85A
challenge studies in the non-human primate (NHP) model, as well
as lessons learned from a recent phase 1 study of Ad5-vectored
Ebola vaccine (Ad5-EBOV). In the NHP study, vaccination with
either intratracheal or aerosol Ad5Ag85A conferred partial pro-
tection as compared to mock vaccination with saline [25]. In the
human trial, a single dose of IM Ad5-EBOV up to 1.6  1011 viral
particles (vp) had an acceptable safety proﬁle and was robustly
immunogenic, even in participants with pre-existing adenovirus
immunity [26].
4. Epidemiological research
Rebecca Harris (LSHTM, UK) modeled epidemiological data to
predict the potential impact of vaccination strategies with new TB
vaccines in an aging population in China. According to Harris's
model, the elderly will suffer most TB cases by 2050 and Mtb
reactivation, as opposed to reinfection, is estimated to become the
main source of incident disease in both the elderly and overall. The
model incorporated elements of possible reduced transmission in
the elderly due to a lower number of social contacts than young
adults based upon data from contact studies in Southern China.
Her results also suggest that the greatest impact would be seen
with a vaccine that is efﬁcacious post-infection and targeted to the
older adult population rather than young adults and adolescents.
Harris highlighted the importance of including older adult and
elderly populations in clinical trials as early as possible in vaccine
development, to ensure that new candidates will be indicated for
the populations that will need them most and provide greatest
population-level impact.
Based on a study using TST and IGRA to determine LTBI prev-
alence rates at four rural sites in China, Dr. Lei Gao (Institute of
Pathogen Biology, Chinese Academy of Medical Sciences and
Peking Union Medical College, China) suggested that current China
LTBI prevalence may be overestimated by TST, as compared to that
measured by IGRA testing. Based on the China CDC 2000 data, an
estimated 44% of Chinese would have LTBI. The newer studies
suggest a signiﬁcantly lower ﬁgure, however [27,28]. Rates may
historically have been elevated by repeat dosing of BCG vaccine.
This study also identiﬁed close contacts, the elderly, and smokers
as high risk groups for disease development, and therefore po-
tential target populations for LTBI monitoring and intervention.
The investigators are repeating TST and IGRA testing in a follow-up
year, which should allow for the ﬁrst accurate prediction of actual
TB infection rates in this population. Initial data from the latency
study would also suggest that new infection rates in the elderly are
signiﬁcant and have been markedly underestimated by the use of
TST alone.
From a retrospective epidemiology study in Southern
Mozambique, a region with high TB-HIV co-infection, Dr. Alberto
Garcia-Basteiro (Manhiça Health Research Center, Mozambique)
presented data that estimates an exceptionally high TB incidence
in young adults living with HIV (847 per 100,000 population [29]).
Further, HIV prevalence in children with TB under 3 years of age
was 44% [30], with TB diagnosed by gastric lavage in 30% of suspect
cases. Given the low case detection rate of 39% in Mozambique
[31], and because only a small proportion of patients receive an-
tiretroviral therapy, HIV and TB co-infection will continue to be a
major public health concern if no drastic improvements are made
soon in diagnosing and treating TB/HIV in this region [32].
Dr. Vidya Mave (Byramjee Jeejeebhoy Medical College–Johns
Hopkins University Clinical Research Site, India) introduced
RePORT India, a joint initiative between the US and India govern-
ments to better evaluate TB infection and disease rates in India.
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with clinical samples to explore speciﬁc questions. As an example,
Cohort for TB Research by the Indo-US Medical Partnership Mul-
ticentric Prospective Observational Study (C-TRIUMPH), a ﬁve-year
prospective observational study consisting of three prospective
cohorts e active TB, household contact and control cohorts e that
aims to investigate both host and microbial factors associated with
TB treatment outcomes, TB disease progression, and TB trans-
mission in India was presented at the Global Forum. Mave dis-
cussed a massive undertaking to collect and store samples from
study participants, which will be applied to future studies.
5. Conclusion
The sessions emphasized that vaccination strategies should be
based on demographic and TB epidemic patterns of a country. In
countries such as China, targeting the elderly might achieve the
greatest impact, whereas in some African countries where HIV
prevalence and burden of TB in young adults are already very high,
vaccinating the adolescent population will likely be of greatest
beneﬁt.
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